Pramipexole

Names

[ Name ]:
Pramipexole

[Synonym ]:
N~6~-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine dihydrochloride
n'-propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine
(Pramipexole )
(S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole
(S)-4,5,6,7-Tetrahydro-N6-propyl-2,6-benzothiazolediamine
(S)-N6-Propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine
[(6S)-2-Amino(4,5,6,7-tetrahydrobenzothiazol-6-yl)]propylamine
(S)-Pramipexole
2,6-BENZOTHIAZOLEDIAMINE,4,5,6,7-TETRAHYDRO-N6-PROPYL-, (6S)-
U 98528E
MFCD00869076
(6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
Pramipexole
(S)-2-AMINO-6-(PROPYLAMINO)-4,5,6,7-TETRAHYDROBENZOTHIAZOL TETRAHYDROBENZOTHIAZOL
T56 BN DSJ CZ GM3 &&S Form
(s)-2-amino-6-propylamino-4,5,6,7-tetrahydrobenzthiazole
Pramipexole(S)-2-Amino-6-propylamino-4,5,6,7-tetrahydrobenzthiazole
2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N-propyl-, (6S)-
(S)-N6-Propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine
(+)-pramipexole
pramipexol
(6S)-N-Propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine

Biological Activity

[Description]:

Pramipexole is a dopamine agonist of the non-ergoline class indicated for treating Parkinson's disease (PD) and restless legs syndrome (RLS).Target: Dopamine Receptor Pramipexole also possesses low/insignificant affinity (500-10,000 nM) for the 5-HT1A, 5-HT1B, 5-HT1D, and α2-adrenergic receptors. It has negligible affinity (>10,000 nM) for the D1, D5, 5-HT2, α1-adrenergic, β-adrenergic, H1, and mACh receptors. All sites assayed were done using human tissues. While pramipexole is used clinically, its D3-preferring receptor binding profile has made it a popular tool compound for preclinical research. Pramipexole has been used (in combination with D2- and or D3-preferring antagonists) to interrogate the role of D3 receptor function in rodent models and tasks for neuropsychiatric disorders [1-3].

[Related Catalog]:

Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor

Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor

Research Areas >> Neurological Disease

[References]

[1]. Kvernmo, T., S. Hartter, and E. Burger, A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther, 2006. 28(8): p. 1065-78.

[2]. Millan, M.J., et al., Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther, 2002. 3

[3]. Weber, M., et al., Heritable strain differences in sensitivity to the startle gating-disruptive effects of D2 but not D3 receptor stimulation. Behav Pharmacol, 2008. 19(8): p. 786-95.

[Related Small Molecules]

Chemical & Physical Properties

[ Density]:
1.2±0.1 g/cm3

[ Boiling Point ]:
378.0±42.0 °C at 760 mmHg

[ Melting Point ]:
288-290°C

[ Molecular Formula ]:
C₁₀H₁₇N₃S

[ Molecular Weight ]:
211.327

[ Flash Point ]:
182.4±27.9 °C

[ Exact Mass ]:
211.114319

[ PSA ]:
79.18000

[ LogP ]:
1.42

[ Vapour Pressure ]:
0.0±0.9 mmHg at 25°C

[ Index of Refraction ]:
1.583

[ Storage condition ]:
-20°C Freezer

MSDS

Click to get detail MSDS

Safety Information

[ Hazard Codes ]:
Xi

[ Risk Phrases ]:
R36/37/38:Irritating to eyes, respiratory system and skin .

[ Safety Phrases ]:
S26-S36

[ WGK Germany ]:
3

[ HS Code ]:
2934999090

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

DownStream

Customs

[ HS Code ]: 2934999090

[ Summary ]:
2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.